Note: When you click on media articles below a new page will open indicating that you are leaving the Marker Therapeutics Website and entering a third-party web site not affiliated with Marker Therapeutics Or any of its affiliates. No information contained in a linked site has been endorsed or approved by Marker Therapeutics And Marker Therapeutics Is not responsible for the content of such third-party website.
TapImmune has entered in a definitive agreement to acquire Marker Therapeutics.
Clinicians in the not-too-distant future may have something new to offer women with breast cancer and ovarian cancer in whom initial therapy fails to yield a response.
TapImmune will be hosting an investor breakfast at the Blackstone hotel tomorrow, May 17th from 7:30am-10am. Come and meet with with Marker Co-Founders Juan Vera, M.D. and Ann Leen, Ph.D., and former President of the American Society for Gene and Cell Therapy Malcolm Brenner along with TapImmune Management.
TapImmune has snapped up privately-owned Marker Therapeutics to create a new company based on a non-genetically engineered, multi-antigen T cell therapy platform.
TapImmune expanded its immuno-oncology capabilities today with a deal to acquire Marker Therapeutics and its clinical-stage, multi-antigen T cell therapy platform.
TapImmune, the Jacksonville-based developer of cancer fighting immunotherapies, is merging with Marker Therapeutics Inc., a Minnesota-based developer of similar T-cell therapies.
Jacksonville local news station, News4Jax, reported TapImmune’s vaccines. Take a look.
Ryan Benk from WJCT had the opportunity to talk with TapImmune President and CEO, Peter Hoang, about our vaccines. Take a look.
TapImmune’s cancer vaccine significantly extended progression free survival of ovarian cancer patients, as compared to the current standard of care.
An investigational vaccine called TPIV200 was found to be safe and generated strong T-cell immunity against tumor cells, significantly delaying recurrence in breast and ovarian cancer patients who had achieved complete responses in a Phase 1 trial.